CN111760121A - Disposable tri-oxygen gas injection therapeutic apparatus - Google Patents
Disposable tri-oxygen gas injection therapeutic apparatus Download PDFInfo
- Publication number
- CN111760121A CN111760121A CN202010658648.3A CN202010658648A CN111760121A CN 111760121 A CN111760121 A CN 111760121A CN 202010658648 A CN202010658648 A CN 202010658648A CN 111760121 A CN111760121 A CN 111760121A
- Authority
- CN
- China
- Prior art keywords
- unit
- gas
- trioxygen
- injection
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title claims abstract description 41
- 239000007924 injection Substances 0.000 title claims abstract description 41
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 17
- 229910001882 dioxygen Inorganic materials 0.000 title claims description 6
- 239000003814 drug Substances 0.000 claims abstract description 25
- 230000000694 effects Effects 0.000 claims abstract description 20
- 230000005611 electricity Effects 0.000 claims abstract description 7
- BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000007789 gas Substances 0.000 claims description 51
- 230000009471 action Effects 0.000 claims description 26
- 238000001914 filtration Methods 0.000 claims description 21
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000001802 infusion Methods 0.000 claims description 7
- 230000003749 cleanliness Effects 0.000 claims description 4
- 238000010253 intravenous injection Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 210000004369 blood Anatomy 0.000 abstract description 29
- 239000008280 blood Substances 0.000 abstract description 29
- 230000001976 improved effect Effects 0.000 abstract description 6
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 230000003197 catalytic effect Effects 0.000 abstract description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 abstract description 2
- 238000009826 distribution Methods 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 230000008733 trauma Effects 0.000 abstract description 2
- 238000009827 uniform distribution Methods 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 8
- 230000002708 enhancing effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 6
- KQBSGRWMSNFIPG-UHFFFAOYSA-N trioxane Chemical compound C1COOOC1 KQBSGRWMSNFIPG-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000000860 Compassion Fatigue Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- XNRNNGPBEPRNAR-UHFFFAOYSA-N Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(O)CC(O)C1CC=CCCCC(O)=O XNRNNGPBEPRNAR-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/165—Filtering accessories, e.g. blood filters, filters for infusion liquids
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
- C25B1/00—Electrolytic production of inorganic compounds or non-metals
- C25B1/01—Products
- C25B1/13—Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0216—Ozone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Anesthesiology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Materials Engineering (AREA)
- Metallurgy (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
The invention provides a disposable injection therapeutic apparatus for trioxyme, and relates to the technical field of medical instruments. This disposable injection therapeutic instrument of trioxyme body, including main control unit, medicament unit, electricity effect unit, filter unit and injection unit all are connected with main control unit, the medicament unit is connected with electricity effect unit, electricity effect unit is connected with filter unit, filter unit and injection unit are connected. The invention improves the treatment effect of ozone, reduces the times of trauma to patients in one treatment, reduces the risk possibly caused by blood leaving human body, and avoids deviation caused by human factors; the distribution uniformity of the trioxane in the blood is improved, the catalytic action is improved, the uniform distribution degree in the blood system of the human body is improved, and the purpose of the whole-body treatment of the trioxane in the blood circulation system of the human body is achieved.
Description
Technical Field
The invention relates to the technical field of medical instruments, in particular to a disposable injection therapeutic apparatus for trioxyme.
Background
Research shows that the trioxane has obvious treatment and recovery effects on treating chronic diseases such as Alzheimer's disease syndrome, hypertension and the like, and the action mechanism of the trioxane comprises the following contents:
three activations: (1) activating erythrocyte metabolism, improving the oxygen saturation of hemoglobin, and enhancing the utilization of oxygen and ATP by tissues; (2) activating immune system of organism, increasing leukocyte in blood, enhancing phagocytic ability, increasing T lymphocyte to 204%, and increasing T active lymphocyte by 70%; (3) activating antioxidant enzyme system, increasing 6-keto prostaglandin F1 level in blood plasma, enhancing antioxidant enzyme activity in vivo, and relieving damage of free radicals to organism;
four purges: (1) removing sugar toxicity and metabolic waste thereof in blood, enhancing the activity of antioxidant enzyme in vivo, and reducing the damage of free radicals to organisms; (2) removing lipotoxin and metabolic waste thereof in blood, improving blood viscosity, enhancing the decomposition of cholesterol and triglyceride and reaching the standard, eliminating recessive damage of lipotoxin to the body, preventing the formation of vascular plaque, and preventing atherosclerosis and nervous system lesion of the whole body; (3) removal of waste products from blood metabolism: such as redundant lactic acid, uric acid, acetone, inorganic salt and the like, so that oxygen supply to tissues is increased, and the blood quality and the cell activity are improved; (4) clearing of toxic cells in blood: eliminating toxic cells in blood, inducing cancer cell death, and reducing canceration hidden danger;
five improvements: (1) improving hemorheology, increasing blood basophilic granulocyte, increasing free heparin level in blood, reducing erythrocyte aggregation, and enhancing deformability; (2) improving microcirculation, relieving cerebral edema, and regulating functional state of cerebral vessels; (3) improving blood metabolism, reducing blood sugar, uric acid, bilirubin, lactic acid, pyruvic acid, lipid peroxide Malondialdehyde (MDA) and thromboxane B2(TXB2), killing various germs, and improving immunity; (4) the state of the blood vessel wall is improved, the platelet aggregation is reduced, and the blood viscosity is reduced, so that the state of the blood vessel wall is improved; (5) improving brain oxygen supply, promoting blood circulation, enhancing brain cell activity, and repairing brain nerve cell.
The existing three oxygen treatment method is to extract the blood of a patient from the body, inject the three oxygen gas into the blood, effectively mix the three oxygen gas and inject the blood back into the body of the patient, so that the treatment process has the problems of blood pollution, misuse and actual effect, the patient has secondary trauma, and the process of blood extraction and two-time blood vessel puncture of spot puncture exists in the treatment process; meanwhile, the trioxyhydrous state can not be preserved for a long time and is reduced into the oxygen state in a short time, the reduction process is a catalytic process, only in the process of the trioxyhydrous reduction and catalysis, the treatment effect can be achieved, the extracorporeal blood trioxyhydrous treatment only can play a role in extracting the part of the blood outside the body, and the treatment effect on the body of a patient can not be well achieved.
Disclosure of Invention
Technical problem to be solved
Aiming at the defects of the prior art, the invention provides a trioxyme disposable injection therapeutic apparatus, which solves the defects and shortcomings in the prior art.
(II) technical scheme
In order to achieve the purpose, the invention is realized by the following technical scheme: the disposable injection therapeutic instrument of trioxyme, including main control unit, medicament unit, electricity effect unit, filter unit and injection unit all are connected with the main control unit, the medicament unit is connected with the electricity effect unit, the electricity effect unit is connected with the filter unit, the filter unit is connected with the injection unit.
Preferably, the main control unit is used for controlling the medicament unit, the electric action unit, the filtering unit and the injection unit.
Preferably, the medicament unit is used for storing pure medical oxygen with high cleanliness, the electric action unit is used for generating trioxygen gas with high concentration, the filtering unit is used for filtering the trioxygen gas, and the injection unit is used for realizing intravenous injection.
Preferably, the therapeutic apparatus comprises the following steps:
s1, storing medical pure oxygen with high cleanliness in the medicament unit as a raw medicament, and introducing the pure oxygen into the electric action unit according to the required amount;
s2, generating a high-concentration trioxygen gas in the electric action unit by the introduced pure oxygen, and introducing the trioxygen gas into the filtering unit;
s3, filtering the high-concentration trioxygen gas in the filtering unit, and then continuously introducing the trioxygen gas into the injection unit;
s4, injecting the trioxygen gas into the saline or sugar water in the injection unit, mixing the trioxygen gas with the saline or sugar water, making the saline or sugar water a transport medium for the trioxygen gas, and delivering the trioxygen gas into the human body in a gaseous form.
Preferably, in the step 4, the following conditions are required to be met when injecting the trioxygen gas into the murphy dropper:
1. maintaining injection pressure P+Infinity P, i.e. the delivery pressure is wirelessly close to normal atmospheric pressure and P is maintained+＞P；
2. Injection gas flow rate should be Q-Infinity Q, i.e. the gas flow rate should be infinitely close to the infusion flow rate and Q should be maintained-＜Q；
3. The gas forming microbubbles whose volume generates a buoyancy force less than the thrust force generated by the flow rate of the liquid, i.e. FFloating body＜FPush away。
(III) advantageous effects
The invention provides a disposable injection therapeutic apparatus for trioxyme. The method has the following beneficial effects:
1. the invention improves the treatment effect of ozone, reduces the times of trauma to patients in one treatment, reduces the risk possibly caused by blood leaving human bodies, and avoids deviation caused by human factors.
2. The invention improves the distribution uniformity of the trioxane in the blood, improves the catalytic action, and achieves the purpose of systemic treatment of the trioxane in the blood circulation system of the human body.
Drawings
FIG. 1 is an overall schematic view of the present invention.
Wherein, 1, a main control unit; 2. a medicament unit; 3. an electric action unit; 4. a filtration unit; 5. an injection unit.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example (b):
as shown in fig. 1, the embodiment of the present invention provides a trioxyme disposable injection therapeutic apparatus, which includes a main control unit 1, a medicament unit 2, an electric action unit 3, a filter unit 4 and an injection unit 5, wherein the medicament unit 2, the electric action unit 3, the filter unit 4 and the injection unit 5 are all connected to the main control unit 1, the medicament unit 2 is connected to the electric action unit 3, the electric action unit 3 is connected to the filter unit 4, the filter unit 4 is connected to the injection unit 5, and the main control unit 1 can be adjusted to meet the effective implementation of different treatment schemes; the electric action unit 3 can replace the action material of electric action, so that the electric action unit can meet the use requirements of different treatment schemes; the medicament unit 2, the filter unit 4 and the injection unit 5 can be replaced to meet the treatment requirements of different treatment schemes.
The main control unit 1 is used for controlling the medicament unit 2, the electric action unit 3, the filter unit 4 and the injection unit 5; the medicament unit 2 is used for storing high-cleanliness pure medical oxygen, the electric action unit 3 is used for generating high-concentration trioxygen gas, the filtering unit 4 is used for filtering the trioxygen gas, and the injection unit 5 is used for realizing intravenous injection.
The therapeutic apparatus is a medical apparatus which carries out the physical catalysis mode of ion level on physical substances according to and applying the technical characteristics of ionization, electrolysis and electrocatalysis, so that the physical change of the ion state of the substances is completed under the condition that the chemical characteristics of the substances are kept unchanged, the activity of the substances is increased, the medical activity can be carried out, and the therapeutic effect can be achieved.
In the invention, the therapeutic apparatus comprises the following use steps:
s1, storing medical pure oxygen with high cleanliness in the medicine unit 2 as a raw medicine, and introducing the pure oxygen into the electric action unit 3 according to the required amount;
s2, introducing pure oxygen to generate a high-concentration trioxygen gas in the electric action unit 3, and introducing the trioxygen gas into the filtering unit 4;
s3, filtering the high-concentration trioxygen gas in the filtering unit 4, and then continuously introducing the trioxygen gas into the injection unit 5;
s4, injecting trioxygen gas into saline or sugar water in the injection unit 5, mixing the trioxygen gas with the saline or sugar water, making the saline or sugar water become a conveying medium of the trioxygen gas, conveying the trioxygen gas into a human body in a gas form, and combining the trioxygen gas with hemoglobin to achieve the purpose of treating certain diseases and generate curative effect.
After the trioxygen gas is generated, the trioxygen gas needs to be injected into a human body, the instability of the trioxygen gas under normal temperature and normal pressure and the water-insoluble characteristic of the trioxygen gas are determined, the trioxygen gas can be rapidly decomposed and reduced into an oxygen state under normal temperature and normal pressure, in order to ensure that the trioxygen gas is injected into the human body, is mixed with blood and has a medical effect, the trioxygen gas is required to be injected into the human body in the trioxygen state, the trioxygen gas is uniformly distributed into the blood through the flowing of the blood and an injection method, the decomposition and oxidation are carried out in the blood, and the therapeutic purpose of the human body.
Intravenous injection is to input liquid into a human body in a mode of dual functions of natural air pressure and liquid pressure, the venous flow rate of the human body is generally kept at 7-8cm/s, the pressure born by liquid medicine comes from the liquid amount in a Murphy's dropper, and the Murphy's dropper is a naturally formed closed space and is equal to the external atmospheric pressure on the premise of no external force action, so that when oxygen is injected into the Murphy's dropper by a trioxane therapeutic apparatus, the pressure environment in the Murphy's dropper cannot be damaged, and the following conditions are required to be achieved when the trioxane is injected into the Murphy's dropper:
1. maintaining injection pressure P+Infinity P, i.e. the delivery pressure is wirelessly close to normal atmospheric pressure and P is maintained+＞P；
2. Injection gas flow rate should be Q-Infinity Q, i.e. the gas flow rate should be infinitely close to the infusion flow rate and Q should be maintained-＜Q；
3. The gas forming microbubbles whose volume generates a buoyancy force less than the thrust force generated by the flow rate of the liquid, i.e. FFloating body＜FPush away。
To satisfy the above conditions, the microbubble generation formula: the volume of the generated microbubbles, the pressure difference with the entering liquid environment, the liquid flow rate and the time (t) for compressing airΔ) Positively correlated, the process formula of the bubble formed by the compressed air is β (F)Floating body＜FPush away)＝{(P+∞P，P+＞P)，(Q-∞Q，Q-＜Q)}*tΔ。
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (5)
1. Disposable injection therapeutic instrument of trioxyme, including main control unit (1), medicament unit (2), electricity effect unit (3), filter unit (4) and injection unit (5), its characterized in that: the medicament unit (2), the electric action unit (3), the filtering unit (4) and the injection unit (5) are all connected with the main control unit (1), the medicament unit (2) is connected with the electric action unit (3), the electric action unit (3) is connected with the filtering unit (4), and the filtering unit (4) is connected with the injection unit (5).
2. The trioxane disposable infusion therapy device of claim 1, wherein: the main control unit (1) is used for controlling the medicament unit (2), the electric action unit (3), the filtering unit (4) and the injection unit (5).
3. The trioxane disposable infusion therapy device of claim 1, wherein: the medicament unit (2) is used for storing high-cleanliness medical pure oxygen, the electric action unit (3) is used for generating high-concentration trioxygen gas, the filtering unit (4) is used for filtering the trioxygen gas, and the injection unit (5) is used for realizing intravenous injection.
4. A trioxane disposable infusion therapy device according to any one of claims 1-3, wherein: the therapeutic apparatus comprises the following use steps:
s1, storing medical pure oxygen with high cleanliness in the medicament unit (2) as a raw medicament, and introducing the pure oxygen into the electric action unit (3) according to the required amount;
s2, generating high-concentration trioxygen gas in the electric action unit (3) by the introduced pure oxygen, and introducing the trioxygen gas into the filtering unit (4);
s3, filtering the high-concentration trioxygen gas in the filtering unit (4), and then continuously introducing the trioxygen gas into the injection unit (5);
s4, injecting trioxygen gas into saline or sugar water in the injection unit (5), mixing the trioxygen gas with the saline or sugar water, making the saline or sugar water become a conveying medium of the trioxygen gas, and conveying the trioxygen gas into a human body in a gas form.
5. A trioxane disposable infusion therapy device according to claim 4, wherein: in the step 4, the three-oxygen gas is injected into the Murphy's dropper, and the following conditions are required to be met when the three-oxygen gas is injected into the Murphy's dropper:
1. maintaining injection pressure P+Infinity P, i.e. the delivery pressure is wirelessly close to normal atmospheric pressure and P is maintained+＞P；
2. Injection gas flow rate should be Q-Infinity Q, i.e. the gas flow rate should be infinitely close to the infusion flow rate and Q should be maintained-＜Q；
3. The gas forming microbubbles whose volume generates a buoyancy force less than the thrust force generated by the flow rate of the liquid, i.e. FFloating body＜FPush away。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010658648.3A CN111760121A (en) | 2020-07-09 | 2020-07-09 | Disposable tri-oxygen gas injection therapeutic apparatus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010658648.3A CN111760121A (en) | 2020-07-09 | 2020-07-09 | Disposable tri-oxygen gas injection therapeutic apparatus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111760121A true CN111760121A (en) | 2020-10-13 |
Family
ID=72726199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010658648.3A Pending CN111760121A (en) | 2020-07-09 | 2020-07-09 | Disposable tri-oxygen gas injection therapeutic apparatus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111760121A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN2912653Y (en) * | 2006-04-04 | 2007-06-20 | 何诺 | Vein oxygen-dissolving therapeutic instrument |
| CN205055021U (en) * | 2015-07-29 | 2016-03-02 | 四川南格尔生物科技有限公司 | Closed ozone filling blood transfusion ware |
| CN207721815U (en) * | 2017-06-07 | 2018-08-14 | 北京新科以仁科技发展有限公司 | A kind of self blood blood sampling recirculation line device |
-
2020
- 2020-07-09 CN CN202010658648.3A patent/CN111760121A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN2912653Y (en) * | 2006-04-04 | 2007-06-20 | 何诺 | Vein oxygen-dissolving therapeutic instrument |
| CN205055021U (en) * | 2015-07-29 | 2016-03-02 | 四川南格尔生物科技有限公司 | Closed ozone filling blood transfusion ware |
| CN207721815U (en) * | 2017-06-07 | 2018-08-14 | 北京新科以仁科技发展有限公司 | A kind of self blood blood sampling recirculation line device |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Viebahn-Hänsler et al. | Ozone in medicine: the low-dose ozone concept—guidelines and treatment strategies | |
| US20030232114A1 (en) | Method for liquid enrichment with oxygen and applications of enriched liquids | |
| WO2008131070A1 (en) | Method for supplying oxygenated water to promote internal healing | |
| US20220362451A1 (en) | Apparatus And Method For Contacting Blood With Ozone | |
| Bocci et al. | Mechanisms of action and chemical-biological interactions between ozone and body compartments: a critical appraisal of the different administration routes | |
| CN105726366B (en) | Skin lipid membrane repairing composition | |
| Auer et al. | Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia | |
| CN111760121A (en) | Disposable tri-oxygen gas injection therapeutic apparatus | |
| KR20010113783A (en) | Method of Providing Cosmetic/Medical Therapy | |
| CN212491008U (en) | Three oxygen gas injection treatment device | |
| JP2021185196A (en) | Composition for treatment of age-related macular degeneration comprising hydrogen | |
| CN204275134U (en) | Hemodilution, clean therapeutic instrument | |
| Bocci et al. | The Actual Six Therapeutic Modalities | |
| RU2414246C2 (en) | Infusion and transfusion therapeutic device | |
| Mohaupt et al. | Brown’s Gas for Health: Background, Observations and Medical Data | |
| Bocci et al. | Ozone therapy in critical patients. Rationale of the therapy and proposed guidelines | |
| CN109020006B (en) | High-stability medical sterilizing saturated hydrogen water at normal temperature and normal pressure and preparation method thereof | |
| RU2758124C1 (en) | Device for intravenous infusions in ozone therapy | |
| WO2024111003A1 (en) | Blood resuscitation and salvage device | |
| RU2683939C1 (en) | Method of intravenous infusion of sodium hypochlorite, activation of glycolysis, treatment of benign and malignant neoplasms, higher effectiveness of chemotherapy of malignant neoplasms, treatment of secondary immune deficiency in generalized bacterial and viral infections | |
| CN202173645U (en) | Traditional Chinese medicine injection quiescent point filtering device | |
| RU72137U1 (en) | DEVICE FOR INFUSION OF OZONIZED PHYSIOLOGICAL SOLUTION | |
| JP2004217610A (en) | Treatment of cancer, diabetes, leukemia and insomnia, and promotion of rejuvenation, cell activation and immunocyte proliferation by physiological saline comprizing deuterium-depleted water | |
| JP2021178785A (en) | Cancer treatment system, combined medicine, and method for suppressing cancer cell proliferation | |
| SU1703073A1 (en) | Method for treating apostematous nephritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201013 |
|
| RJ01 | Rejection of invention patent application after publication |